Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the ...

No new treatments for schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric ...

For the past 70 years, schizophrenia treatments all targeted the same chemical: dopamine. While that works for some, it ...

Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. | Intra-Cellular ...

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through ...

Bristol Myers’ $1.5 billion restructuring initiative that runs through 2025 may not be the end of the company’s ongoing efficiency push.  | Bristol Myers' $1.5 billion restructuring initiative that ...

Leal Therapeutics has secured yet another multi-million financing deal as the Worcester-based biotechnology startup has ...

Bristol Myers Squibb Q3 revenue rose 8% YoY to $11.89 billion, driven by strong Growth Portfolio sales, especially Eliquis.

An AI model can predict dual-target drugs that can inhibit two enzymes at the same time to treat complex diseases and ...

A new study finds poor attention spans in childhood, plus certain genes, could play a role in raising the risk for psychosis, ...

Prosecutors, defense attorneys and a Manhattan judge spent nearly two weeks selecting 12 jurors and four alternates for the ...